Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Conditions
Ovarian Clear Cell Adenocarcinoma · Platinum-Sensitive Ovarian Carcinoma · Recurrent Endometrial Serous Adenocarcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Fallopian Tube Endometrioid Adenocarcinoma · Recurrent Fallopian Tube Serous Adenocarcinoma · Recurrent Ovarian Carcinoma · Recurrent Ovarian Clear Cell Adenocarcinoma · Recurrent Ovarian Endometrioid Adenocarcinoma · Recurrent Ovarian Serous Adenocarcinoma · Recurrent Platinum-Resistant Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma · Recurrent Primary Peritoneal Clear Cell Adenocarcinoma · Recurrent Primary Peritoneal Endometrioid Adenocarcinoma · Recurrent Primary Peritoneal Serous Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Roswell Park Cancer Institute, Buffalo, New York, United States
Contact: Principal Investigator (Emese Zsiros)M D Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Amir A. Jazaeri)
Study leads
Emese Zsiros
Principal Investigator
Roswell Park Cancer Institute